<DOC>
	<DOCNO>NCT02981602</DOCNO>
	<brief_summary>To examine safety tolerability IONIS-HBVRx administration treatment-naive patient chronic hepatitis B virus infection</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Antiviral Activity IONIS-HBVRx Treatment-Naïve Patients With Chronic HBV Infection</brief_title>
	<detailed_description>This study examine effect IONIS-HBVRx placebo ( 3:1 randomization ) administer subcutaneously treatment-naïve patient chronically infect HBV effect subsequent nucleos ( ) ide analogue treatment patient .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Age 18 70 year Chronic HBV infection ≥6 month ( e.g. , positive serum HBsAg ≥ 6 month ) Plasma HBV DNA ≥ 2 x 1000 IU/mL Serum HBsAg ≥ 50 IU/mL Current prior receipt antiHBV nucleos ( ) ide analogue therapy . Patients fail prior interferon treatment , great 6 month prior Screening , may evaluate possible participation study History liver cirrhosis and/or evidence cirrhosis determine follow : 1 . Liver biopsy ( i.e. , Metavir Score F4 ) within 2 year Screening , 2 . Fibroscan &gt; 12 KPa , within 12 month Screening , 3 . ASTtoPlatelet Index ( APRI ) &gt; 2 Fibrosure result &gt; 0.7 within 12 month Screening For patient without test cirrhosis timeframes , Fibroscan , APRI Fibrosure , may perform screen period rule cirrhosis History liver failure evidence ascites , hepatic encephalopathy , and/or gastric esophageal varix History liver disease Hepatitis B Coinfection hepatitis C virus ( HCV ) , human immunodeficiency virus ( HIV ) , hepatitis D virus ( HDV ) BMI &gt; 35 kg/m2 History , suspect presence vasculitis Received solid organ bone marrow transplant Currently take , take within 3 month Screening , immunosuppressing drug ( e.g. , prednisone ) Diagnosed hepatocellular carcinoma suspect hepatocellular carcinoma evidence screen alphafetoprotein ≥ 200 ng/mL . If screen alphafetoprotein ≥ 50 ng/mL &lt; 200 ng/mL , absence liver mass must document image within 6 month randomization Clinicallysignificant abnormality aside chronic HBV infection medical history ( e.g. , previous acute coronary syndrome within 6 month Screening , major surgery within 3 month Screening , uncontrolled diabetes ) physical examination History bleed diathesis coagulopathy History extrahepatic disorder possibly relate HBV immune complex ( e.g. , glomerulonephritis , polyarteritis nodosa ) History excess alcohol consumption within 6 month Screening History drug abuse dependence , recreational use drug : within 3 month Screening soft drug ( marijuana ) within 1year Screening hard drug ( cocaine , phencyclidine [ PCP ] )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Hepatitis</keyword>
	<keyword>Chronic</keyword>
	<keyword>HBV</keyword>
</DOC>